Altimmune, Inc. - Common Stock (NQ:ALT)

2.670 -0.060 (-2.20%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

20 21 Next >

Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment' ↗

May 07, 2024

Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money."

Via Benzinga

Peering Into Altimmune's Recent Short Interest ↗

April 30, 2024

Via Benzinga

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 29, 2024

Via Benzinga

How Is The Market Feeling About Altimmune? ↗

April 08, 2024

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today ↗

April 03, 2024

Via Benzinga

ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 ↗

March 27, 2024

ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Altimmune's Earnings Outlook ↗

March 26, 2024

Via Benzinga

Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

April 29, 2024

Via Benzinga

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains ↗

April 24, 2024

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

Via InvestorPlace

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

April 22, 2024

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio

Via MarketBeat

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential ↗

April 20, 2024

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

Via The Motley Fool

(ALT) - Analyzing Altimmune's Short Interest ↗

March 22, 2024

Via Benzinga

Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today ↗

March 18, 2024

Via Benzinga

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 ↗

April 11, 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

Via InvestorPlace

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead. ↗

April 09, 2024

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

Via The Motley Fool

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

April 09, 2024

Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market

Via MarketBeat

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday ↗

March 28, 2024

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat...

Via Benzinga

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 28, 2024

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of...

Via Benzinga

Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review ↗

March 28, 2024

The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break.

Via Investor's Business Daily

7 Stocks That Will Drive the Weight Loss Drugs Market

March 28, 2024

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Via MarketBeat

Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday? ↗

March 27, 2024

Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 27, 2024

Via Benzinga

Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On' ↗

March 19, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.

Via Benzinga

Earnings Scheduled For March 27, 2024 ↗

March 27, 2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

Via Benzinga

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market? ↗

March 15, 2024

Viking Therapeutics just might be an attractive acquisition target for Pfizer.

Via The Motley Fool

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

March 03, 2024

WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...

Via NewMediaWire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

March 03, 2024

Via TheNewswire.com

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

March 01, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

March 01, 2024

WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...

Via TheNewswire.com

Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review ↗

March 01, 2024

The Nasdaq is on the cusp of setting a record high.

Via Investor's Business Daily

Topics Economy

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.